← Leaderboards
Jeffrey L Ives
Acumen Pharmaceuticals, Inc.
$2,836,536
Attributed
$2,836,536
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$2,836,536 · 2
By mechanism
U01$2,836,536 · 2
Top collaborators
No co-investigators on record.
Most similar at Acumen Pharmaceuticals, Inc.
Same institution · by research overlap
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAdverse EffectsBiodistributionAgedBehavioralAmyloid Beta-ProteinAnalytical MethodAnimalsAntibodiesBaseChronicBindingBinding ProteinsBiochemicalAffinityBiological MarkersBlood - Brain Barrier AnatomyBrainCause Of DeathCell BankCell LineCgmp ProductionAcuteAbeta Oligomer
Grant awards (4)
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$1,135,517
U01 · FY2019 · AG · contact PI
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$1,256,516
U01 · FY2018 · AG · contact PI
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$354,369
U01 · FY2017 · AG · contact PI
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$90,134
U01 · FY2017 · AG · contact PI